Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1314

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]